ReviewExperimental & molecular medicine2025
Regulation of transcriptome plasticity by mTOR signaling pathway.
Review in Experimental & molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Molecular Mechanisms of Hippocampal Synaptic Plasticity Disruption Induced by Chronic Methamphetamine Exposure: A Narrative Review.Cellular and molecular neurobiology · 2026Review
- Osteoarthritis and dementia: contrasting disorders driven by mutual pathways of autophagy, mTOR, GLP-1, AMPK, Wnt, and WISP1.Expert review of clinical pharmacology · 2026Review
- The messenger ion: magnesium ion coordinates bone marrow mesenchymal stem cells-mediated osteogenesis, migration, and angiogenesis via the PI3K-AKT-mTOR pathway.Stem cell research & therapy · 2026Article
- Viral-host interactions mediated by the mTOR signaling pathway.Cell insight · 2026Review
- Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- Running out the clock: Circadian rhythm dysfunction in cognitive disease.International review of neurobiology · 2026Review
- mTOR signaling in cholangiocarcinoma: mechanistic insights and therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Cannabis and Cannabidiol: Pioneering Treatment for the Nervous System with Alzheimer's Disease and Peripheral Organ Involvement with Nonalcoholic Fatty Liver Disease (NAFLD).Current neurovascular research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The mechanistic target of rapamycin (mTOR) pathway, long recognized for its critical roles in cellular metabolism and growth, is increasingly appreciated for its regulatory impact on the transcriptome. Recent insights into mTOR's regulation of alternative splicing and polyadenylation reveal a sophisticated mechanism by which mTOR influences RNA processing to affect the proteome's diversity and functionality. Here, in this Review, we delve into the multifaceted roles of mTOR in modulating transcriptome plasticity, highlighting its influence beyond traditional functions such as protein synthesis and cell growth. By examining the latest findings, we explore how mTOR-mediated transcriptome plasticity plays a pivotal role in cellular adaptation and pathogenesis. Studies indicate that mTOR modulation of RNA processing pathways enables cells to respond dynamically to environmental and metabolic cues, thereby altering protein function and cellular behavior in a context-dependent manner. This capability is crucial for both normal physiological responses and the development of disease. The Review also discusses the implications of these findings for understanding complex biological systems and diseases, particularly cancer, where mTOR's regulation of transcript diversity could drive tumor heterogeneity and treatment resistance. As research continues to uncover the extensive influence of mTOR on RNA processing, it becomes clear that a comprehensive understanding of these mechanisms is essential for the development of targeted therapies and the prediction of their outcomes in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.